ArticleKorean journal of clinical oncology2020
The current status of cancer survivorship care and a consideration of appropriate care model in Korea.
Article in Korean journal of clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 10 citations in OpenAlex.
- Social Reintegration Experiences of Young Adult Cancer Survivors.Behavioral sciences (Basel, Switzerland) · 2024Article
- Association between Regular Use of Analgesics before Cancer Diagnosis and Occurrence of Mood Disorders.Nursing reports (Pavia, Italy) · 2024Article
- Health Behaviors of Cancer Survivors According to the Employment Status and Occupation: A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2023Article
- Analysis of Perceptions, Preferences, and Participation Intention of Urban Forest Healing Program among Cancer Survivors.International journal of environmental research and public health · 2023Article
- Factors to improve distress and fatigue in Cancer survivorship; further understanding through text analysis of interviews by machine learning.BMC cancer · 2021Article
- The mediating effect of social support on uncertainty in illness and quality of life of female cancer survivors: a cross-sectional study.Health and quality of life outcomes · 2020Article
- Prerequisites for Effective Implementation of Telemedicine: Focusing on Current Situations in Korea.Healthcare informatics research · 2015Review
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Breast cancer patients with a human epidermal growth factor receptor 2 (HER2) enriched subtype are known to have higher rates of brain metastases (BM) than other patients. This study aimed to evaluate treatment options and survival outcomes. Methods: A total of 115 breast cancer brain metastases (BCBM) patients with nearly complete medical records were retrospectively analyzed. Additionally, 36 patients were HER2 enriched types according to histological subtypes. The BM was found by brain magnetic resonance imaging in patients who had neurologic symptoms or by regular screening. Age, breast tumor size, number of BM, histological subtypes, first treatment of breast cancer, estrogen receptor, and HER2 status, stage, local treatment of BM were analyzed. Median overall survival, 5-year survival were analyzed from the data. Results: The median survival time after BM was 6 months, the mean survival time was 16.3 months, and the 5-year survival after BM was only 8.0%. Factors that significantly affect the survival of BCBM patients include histological subtype, number of BM, use of lapatinib in multivariate analysis. A total of 19 out of 36 HER2 enriched patients were treated with lapatinib or capecitabine. For the treatment of HER2 enriched patients, additional use of blood-brain barrier (BBB) crossing substances, as well as local treatment for BM, significantly improve the survival rate in the Kaplan-Meier method (P=0.001). Conclusion: A combination of local treatment modality for BCBM and the use of substances that cross the BBB for the HER2 enriched patient improved the survival rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.